{"pmid":32463078,"title":"Decreased myocardial infarction admissions during COVID times: what can we learn?","text":["Decreased myocardial infarction admissions during COVID times: what can we learn?","Cardiovasc Res","Niccoli, Giampaolo","Luescher, Thomas F","Crea, Filippo","32463078"],"journal":"Cardiovasc Res","authors":["Niccoli, Giampaolo","Luescher, Thomas F","Crea, Filippo"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32463078","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/cvr/cvaa146","keywords":["acute coronary syndromes","acute myocardial infarction","covid-19","sars-cov-2"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668079521539031040,"score":9.490897,"similar":[{"pmid":32499236,"title":"COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?","text":["COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?","The initial mechanism for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is the binding of the virus to the membrane-bound form of ACE2, which is mainly expressed in the lung. Since the heart and the vessels also express ACE2, they both could become targets of the virus. However, at present the extent and importance of this potential involvement are unknown. Cardiac troponin levels are significantly higher in patients with more severe infections, patients admitted to intensive care units or in those who have died. In the setting of COVID-19, myocardial injury, defined by an increased troponin level, occurs especially due to non-ischaemic myocardial processes, including severe respiratory infection with hypoxia, sepsis, systemic inflammation, pulmonary thrombosis and embolism, cardiac adrenergic hyperstimulation during cytokine storm syndrome, and myocarditis. At present, there are limited reports on definite diagnosis of myocarditis caused by SARS-CoV-2 in humans and limited demonstration of the virus in the myocardium. In conclusion, although the heart and the vessels are potential targets in COVID-19, there is currently limited evidence on the direct infection of the myocardium by SARS-CoV-2. Additional pathological studies and autopsy series will be very helpful to clarify the potentiality of COVID-19 to directly infect the myocardium and cause myocarditis.","Heart","Imazio, Massimo","Klingel, Karin","Kindermann, Ingrid","Brucato, Antonio","De Rosa, Francesco Giuseppe","Adler, Yehuda","De Ferrari, Gaetano Maria","32499236"],"abstract":["The initial mechanism for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is the binding of the virus to the membrane-bound form of ACE2, which is mainly expressed in the lung. Since the heart and the vessels also express ACE2, they both could become targets of the virus. However, at present the extent and importance of this potential involvement are unknown. Cardiac troponin levels are significantly higher in patients with more severe infections, patients admitted to intensive care units or in those who have died. In the setting of COVID-19, myocardial injury, defined by an increased troponin level, occurs especially due to non-ischaemic myocardial processes, including severe respiratory infection with hypoxia, sepsis, systemic inflammation, pulmonary thrombosis and embolism, cardiac adrenergic hyperstimulation during cytokine storm syndrome, and myocarditis. At present, there are limited reports on definite diagnosis of myocarditis caused by SARS-CoV-2 in humans and limited demonstration of the virus in the myocardium. In conclusion, although the heart and the vessels are potential targets in COVID-19, there is currently limited evidence on the direct infection of the myocardium by SARS-CoV-2. Additional pathological studies and autopsy series will be very helpful to clarify the potentiality of COVID-19 to directly infect the myocardium and cause myocarditis."],"journal":"Heart","authors":["Imazio, Massimo","Klingel, Karin","Kindermann, Ingrid","Brucato, Antonio","De Rosa, Francesco Giuseppe","Adler, Yehuda","De Ferrari, Gaetano Maria"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32499236","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1136/heartjnl-2020-317186","keywords":["acute coronary syndromes","myocarditis","pericardial effusion","thromboembolic pulmonary vascular disease"],"locations":["hypoxia","cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668890966313926657,"score":86.25167},{"pmid":32398246,"title":"Flattening the curve in COVID-19 using personalised protective equipment: lessons from air pollution.","text":["Flattening the curve in COVID-19 using personalised protective equipment: lessons from air pollution.","Heart","Rajagopaian, Sanjay","Huang, Sui","Brook, Robert D","32398246"],"journal":"Heart","authors":["Rajagopaian, Sanjay","Huang, Sui","Brook, Robert D"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32398246","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1136/heartjnl-2020-317104","keywords":["acute coronary syndromes","acute myocardial infarction","global healthcare delivery","healthcare delivery"],"topics":["Prevention"],"weight":1,"_version_":1666714494826446848,"score":80.81137},{"pmid":32311816,"title":"Management of Acute Myocardial Infarction During the COVID-19 Pandemic.","text":["Management of Acute Myocardial Infarction During the COVID-19 Pandemic.","The worldwide pandemic caused by the novel acute respiratory syndrome coronavirus 2 (SARS-CoV2) has resulted in a new and lethal disease termed coronavirus disease 2019 (COVID-19). Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with COVID-19. The objective of this document is to provide recommendations for a systematic approach for the care of patients with an acute myocardial infarction (AMI) during the COVID-19 pandemic. There is a recognition of two major challenges in providing recommendations for AMI care in the COVID-19 era. Cardiovascular manifestations of COVID-19 are complex with patients presenting with AMI, myocarditis simulating a ST-elevation MI presentation, stress cardiomyopathy, non-ischemic cardiomyopathy, coronary spasm, or nonspecific myocardial injury and the prevalence of COVID-19 disease in the US population remains unknown with risk of asymptomatic spread. This document addresses the care of these patients focusing on 1) the varied clinical presentations; 2) appropriate personal protection equipment (PPE) for health care workers; 3) role of the Emergency Department, Emergency Medical System and the Cardiac Catheterization Laboratory; and 4) Regional STEMI systems of care. During the COVID-19 pandemic, primary PCI remains the standard of care for STEMI patients at PCI capable hospitals when it can be provided in a timely fashion, with an expert team outfitted with PPE in a dedicated CCL room. A fibrinolysis-based strategy may be entertained at non-PCI capable referral hospitals or in specific situations where primary PCI cannot be executed or is not deemed the best option. This article is protected by copyright. All rights reserved.","Catheter Cardiovasc Interv","Mahmud, Ehtisham","Dauerman, Harold L","Welt, Frederick Gp","Messenger, John C","Rao, Sunil V","Grines, Cindy","Mattu, Amal","Kirtane, Ajay J","Jauhar, Rajiv","Meraj, Perwaiz","Rokos, Ivan C","Rumsfeld, John S","Henry, Timothy D","32311816"],"abstract":["The worldwide pandemic caused by the novel acute respiratory syndrome coronavirus 2 (SARS-CoV2) has resulted in a new and lethal disease termed coronavirus disease 2019 (COVID-19). Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with COVID-19. The objective of this document is to provide recommendations for a systematic approach for the care of patients with an acute myocardial infarction (AMI) during the COVID-19 pandemic. There is a recognition of two major challenges in providing recommendations for AMI care in the COVID-19 era. Cardiovascular manifestations of COVID-19 are complex with patients presenting with AMI, myocarditis simulating a ST-elevation MI presentation, stress cardiomyopathy, non-ischemic cardiomyopathy, coronary spasm, or nonspecific myocardial injury and the prevalence of COVID-19 disease in the US population remains unknown with risk of asymptomatic spread. This document addresses the care of these patients focusing on 1) the varied clinical presentations; 2) appropriate personal protection equipment (PPE) for health care workers; 3) role of the Emergency Department, Emergency Medical System and the Cardiac Catheterization Laboratory; and 4) Regional STEMI systems of care. During the COVID-19 pandemic, primary PCI remains the standard of care for STEMI patients at PCI capable hospitals when it can be provided in a timely fashion, with an expert team outfitted with PPE in a dedicated CCL room. A fibrinolysis-based strategy may be entertained at non-PCI capable referral hospitals or in specific situations where primary PCI cannot be executed or is not deemed the best option. This article is protected by copyright. All rights reserved."],"journal":"Catheter Cardiovasc Interv","authors":["Mahmud, Ehtisham","Dauerman, Harold L","Welt, Frederick Gp","Messenger, John C","Rao, Sunil V","Grines, Cindy","Mattu, Amal","Kirtane, Ajay J","Jauhar, Rajiv","Meraj, Perwaiz","Rokos, Ivan C","Rumsfeld, John S","Henry, Timothy D"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311816","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/ccd.28946","keywords":["covid-19","stemi","acute myocardial infarction","emergency medical system","fibrinolysis","percutaneous coronary intervention"],"locations":["US"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1666138491218558976,"score":76.65776},{"pmid":32330544,"pmcid":"PMC7173829","title":"Management of Acute Myocardial Infarction During the COVID-19 Pandemic.","text":["Management of Acute Myocardial Infarction During the COVID-19 Pandemic.","The worldwide pandemic caused by the novel acute respiratory syndrome coronavirus 2 (SARS-CoV2) has resulted in a new and lethal disease termed coronavirus disease 2019 (COVID-19). Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with COVID-19. The objective of this document is to provide recommendations for a systematic approach for the care of patients with an acute myocardial infarction (AMI) during the COVID-19 pandemic. There is a recognition of two major challenges in providing recommendations for AMI care in the COVID-19 era. Cardiovascular manifestations of COVID-19 are complex with patients presenting with AMI, myocarditis simulating a ST-elevation MI presentation, stress cardiomyopathy, non-ischemic cardiomyopathy, coronary spasm, or nonspecific myocardial injury and the prevalence of COVID-19 disease in the US population remains unknown with risk of asymptomatic spread. This document addresses the care of these patients focusing on 1) the varied clinical presentations; 2) appropriate personal protection equipment (PPE) for health care workers; 3) role of the Emergency Department, Emergency Medical System and the Cardiac Catheterization Laboratory; and 4) Regional STEMI systems of care. During the COVID-19 pandemic, primary PCI remains the standard of care for STEMI patients at PCI capable hospitals when it can be provided in a timely fashion, with an expert team outfitted with PPE in a dedicated CCL room. A fibrinolysis-based strategy may be entertained at non-PCI capable referral hospitals or in specific situations where primary PCI cannot be executed or is not deemed the best option.","J Am Coll Cardiol","Mahmud, Ehtisham","Dauerman, Harold L","Welt, Frederick Gp","Messenger, John C","Rao, Sunil V","Grines, Cindy","Mattu, Amal","Kirtane, Ajay J","Jauhar, Rajiv","Meraj, Perwaiz","Rokos, Ivan C","Rumsfeld, John S","Henry, Timothy D","32330544"],"abstract":["The worldwide pandemic caused by the novel acute respiratory syndrome coronavirus 2 (SARS-CoV2) has resulted in a new and lethal disease termed coronavirus disease 2019 (COVID-19). Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with COVID-19. The objective of this document is to provide recommendations for a systematic approach for the care of patients with an acute myocardial infarction (AMI) during the COVID-19 pandemic. There is a recognition of two major challenges in providing recommendations for AMI care in the COVID-19 era. Cardiovascular manifestations of COVID-19 are complex with patients presenting with AMI, myocarditis simulating a ST-elevation MI presentation, stress cardiomyopathy, non-ischemic cardiomyopathy, coronary spasm, or nonspecific myocardial injury and the prevalence of COVID-19 disease in the US population remains unknown with risk of asymptomatic spread. This document addresses the care of these patients focusing on 1) the varied clinical presentations; 2) appropriate personal protection equipment (PPE) for health care workers; 3) role of the Emergency Department, Emergency Medical System and the Cardiac Catheterization Laboratory; and 4) Regional STEMI systems of care. During the COVID-19 pandemic, primary PCI remains the standard of care for STEMI patients at PCI capable hospitals when it can be provided in a timely fashion, with an expert team outfitted with PPE in a dedicated CCL room. A fibrinolysis-based strategy may be entertained at non-PCI capable referral hospitals or in specific situations where primary PCI cannot be executed or is not deemed the best option."],"journal":"J Am Coll Cardiol","authors":["Mahmud, Ehtisham","Dauerman, Harold L","Welt, Frederick Gp","Messenger, John C","Rao, Sunil V","Grines, Cindy","Mattu, Amal","Kirtane, Ajay J","Jauhar, Rajiv","Meraj, Perwaiz","Rokos, Ivan C","Rumsfeld, John S","Henry, Timothy D"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330544","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jacc.2020.04.039","keywords":["covid-19","stemi","acute myocardial infarction","emergency medical system","fibrinolysis","percutaneous coronary intervention"],"locations":["US"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1666138494629576708,"score":76.65776},{"pmid":32412631,"title":"Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era.","text":["Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era.","AIMS: To evaluate the impact of the COVID-19 pandemic on patient admissions to Italian cardiac care units (CCUs). METHODS AND RESULTS: We conducted a multicentre, observational, nationwide survey to collect data on admissions for acute myocardial infarction (AMI) at Italian CCUs throughout a 1 week period during the COVID-19 outbreak, compared with the equivalent week in 2019. We observed a 48.4% reduction in admissions for AMI compared with the equivalent week in 2019 (P < 0.001). The reduction was significant for both ST-segment elevation myocardial infarction [STEMI; 26.5%, 95% confidence interval (CI) 21.7-32.3; P = 0.009] and non-STEMI (NSTEMI; 65.1%, 95% CI 60.3-70.3; P < 0.001). Among STEMIs, the reduction was higher for women (41.2%; P = 0.011) than men (17.8%; P = 0.191). A similar reduction in AMI admissions was registered in North Italy (52.1%), Central Italy (59.3%), and South Italy (52.1%). The STEMI case fatality rate during the pandemic was substantially increased compared with 2019 [risk ratio (RR) = 3.3, 95% CI 1.7-6.6; P < 0.001]. A parallel increase in complications was also registered (RR = 1.8, 95% CI 1.1-2.8; P = 0.009). CONCLUSION: Admissions for AMI were significantly reduced during the COVID-19 pandemic across Italy, with a parallel increase in fatality and complication rates. This constitutes a serious social issue, demanding attention by the scientific and healthcare communities and public regulatory agencies.","Eur Heart J","De Rosa, Salvatore","Spaccarotella, Carmen","Basso, Cristina","Calabro, Maria Pia","Curcio, Antonio","Filardi, Pasquale Perrone","Mancone, Massimo","Mercuro, Giuseppe","Muscoli, Saverio","Nodari, Savina","Pedrinelli, Roberto","Sinagra, Gianfranco","Indolfi, Ciro","32412631"],"abstract":["AIMS: To evaluate the impact of the COVID-19 pandemic on patient admissions to Italian cardiac care units (CCUs). METHODS AND RESULTS: We conducted a multicentre, observational, nationwide survey to collect data on admissions for acute myocardial infarction (AMI) at Italian CCUs throughout a 1 week period during the COVID-19 outbreak, compared with the equivalent week in 2019. We observed a 48.4% reduction in admissions for AMI compared with the equivalent week in 2019 (P < 0.001). The reduction was significant for both ST-segment elevation myocardial infarction [STEMI; 26.5%, 95% confidence interval (CI) 21.7-32.3; P = 0.009] and non-STEMI (NSTEMI; 65.1%, 95% CI 60.3-70.3; P < 0.001). Among STEMIs, the reduction was higher for women (41.2%; P = 0.011) than men (17.8%; P = 0.191). A similar reduction in AMI admissions was registered in North Italy (52.1%), Central Italy (59.3%), and South Italy (52.1%). The STEMI case fatality rate during the pandemic was substantially increased compared with 2019 [risk ratio (RR) = 3.3, 95% CI 1.7-6.6; P < 0.001]. A parallel increase in complications was also registered (RR = 1.8, 95% CI 1.1-2.8; P = 0.009). CONCLUSION: Admissions for AMI were significantly reduced during the COVID-19 pandemic across Italy, with a parallel increase in fatality and complication rates. This constitutes a serious social issue, demanding attention by the scientific and healthcare communities and public regulatory agencies."],"journal":"Eur Heart J","authors":["De Rosa, Salvatore","Spaccarotella, Carmen","Basso, Cristina","Calabro, Maria Pia","Curcio, Antonio","Filardi, Pasquale Perrone","Mancone, Massimo","Mercuro, Giuseppe","Muscoli, Saverio","Nodari, Savina","Pedrinelli, Roberto","Sinagra, Gianfranco","Indolfi, Ciro"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412631","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1093/eurheartj/ehaa409","keywords":["acute myocardial infarction","covid-19","cardiac care units","sars-cov2","stemi"],"locations":["Italian","Italian","North Italy","South Italy","Italy","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666897319137640448,"score":74.56644}]}